THE ¹³C-NMR SPECTRUM OF MITOMYCIN C: REASSIGNMENT

PAUL J. KELLER and ULFERT HORNEMANN¹

Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN 47907

ABSTRACT.—The ¹³C-nmr spectrum of the antitumor antibiotic mitomycin C was first reported in 1974 by Lown and Begleiter who provided reasonable, but not unambiguous, assignments. The need for unambiguous ¹³C-nmr assignments of mitomycin C for biosynthetic studies and mode of action studies prompted our reinvestigation. The use of various proton decoupling techniques, ¹⁵N-labeling, and spectral comparisons with decarbamoylmitomycin C led to unambiguous assignments for all of the resonances in the mitomycin C ¹³C-nmr spectrum and, thus, to a revision of the published assignments for C-5, C-6, C-8, C-8a, and C-9a.

Mitomycin C (1) is a member of a group of closely related antitumor antibiotics that are produced by various species of *Streptomyces* (1). Mitomycin C is currently in clinical use as an anticancer agent (2).

In preparation for continued biosynthetic and mode of action studies on mitomycins (3,4), we found it necessary to re-examine the assignments previously published by Lown and Begleiter (5) for the ¹³C-nmr spectrum of mitomycin C. The work of these authors relied on proton-noise-decoupled and off-resonance-decoupled spectra, as well as on chemical shift comparisons with model compounds, and yielded reasonable, but not unambiguous, assignments. However the high degree of unsaturation and the presence of a pseudo-center of symmetry in the quinone ring make the carbon assignments difficult. In the present work, the assignment of the ¹³C-nmr spectrum of mitomycin C was investigated by several means including: ¹H-broadband decoupling, gated ¹H-decoupling, single frequency off-resonance decoupling (SFORD), low-power selective proton decoupling, ¹⁵N-labeling, and spectral comparisons with decarbamoylmitomycin C (2).

EXPERIMENTAL

¹³C-nmr spectra of mitomycin C (0.2 M in 2.3 ml of pyridine- d_5) were measured at 50.3 MHz on either a Varian XL-200 spectrometer or a Nicolet NT-200 instrument, which were operated in FT mode: pulse angle = 45°, acquisition time = 1.5 sec, repetition time = 3.0 sec, sweep width = \pm 5500 Hz, 32 K data sets. Gated (decoupler off only during acquisition) and continuous broadband ¹H-decoupled spectra were obtained by square wave modulation of the decoupler frequency. SFORD experiments were conducted with the proton decoupler set at -2.5 ppm and $\gamma_{\rm H}H_2/2\pi$ = 2.85 KHz. Low power selective pro-



¹Present address: School of Pharmacy, University of Wisconsin, Madison, WI 53706.

ton decoupling was accomplished with a decoupler power which gave $\gamma_H H_2/2\pi = 116$ Hz. The ¹H-nmr spectrum of the same sample of mitomycin C used for the ¹³C-nmr experiments was measured on a Varian FT-80 instrument: pulse angle = 60°, acquisition time = 4.1 sec, repetition time = 7.1 sec, sweep width = 1000 Hz, 8 K data sets. All chemical shifts are referenced to internal TMS.

 $(C_7$ -¹⁵NH₂)-Mitomycin C (**3**) was prepared from mitomycin A (**4**), which was adsorbed on silica gel and then slurried in a mixture of hexanes and exposed to ¹⁵N-ammonia for 12 h (6). Decarbamoylmitomycin C was prepared by the method of Kinoshita *et al.* (7) through reaction of mitomycin C with sodium methoxide. Both compounds exhibited the expected spectral characteristics.

RESULTS AND DISCUSSION

The results obtained in the SFORD experiment (table 1) in conjunction with the ¹H-nmr assignments for mitomycin C² established by Lown and Begleiter (5) and the results obtained through analysis of one bond and long-range ¹H-¹³C couplings, yield assignments for the protonated carbons of **1** which conform to the published assignments (5). The nonprotonated carbon signals, which comprise the remainder of the spectrum, are found in three spectral regions: three peaks at 104-111 ppm, three peaks at 149-159 ppm, and two signals at 176-179 ppm.

Assignments ^a							$I^{r/1}I$	3 ^d	2 ^e	2
New	Old	ppmª	Height ^a	¹ <i>J</i> с-н ^ь	^{2,3} Јс-н ^ь	۶r۲	× 100	ррт	ppm	Height
5	8	178.3	21	s	3, q	_	_	179.0	178.5	15
8	5	176.7	38	s	5, t	_	_	177.1	177.3	32
10a	10a	158.1	81	s	s		—	159.6		
5a	5a	156.1	32	s	s		—	157.4	156.0	22
7	7	149.6	nm ^f	s	nm			151.6 ^g	149.8	nm
8a	9a	110.7	65	s	7, d	—		110.6	113.0	27
9a	6,8a	106.8	44	s	m			107.3	107.6	22
6	6,8a	104.3	80	s	5,q	—		104.9	104.1	53
10	10	62.5	100	150, t	8, d	81	54	63.1	61.3	91
3	3	50.6	87	146, t	m	65	45	50.8	50.7	91
OMe	OMe	49.5	89	142, q	s	60	42	nm ^f	49.6	71
9	9	44.2	79	134, d	s	64	48	44.4	47.9	100
1	1	36.7	65	181, d	m	76	42	37.5	36.5	56
2	2	32.6	57	182, d	m	68	37	33.5	33.5	42
6a	6a	8.8	98	127,q	s	40	31	8.1	8.8	86
			1							

 TABLE 1
 50.3 MHz
 ¹³C-nmr data for mitomycin C and related compounds.

All J values are in Hertz.

^{a1}H-decoupled data for mitomycin C (1).

^bGated decoupling experiment for (1).

SFORD experiment for (1).

^d33 mg in 2.3 ml of methanol- d_4 .

^e48 mg in 2.3 ml of pyridine- d_5 .

^fPartially obscured by solvent, nm = not measured.

^gDoublet, J = 17 Hz.

The three resonances in the high-field aromatic region are expected to be due to C-6, C-8a, and C-9a on the basis of their chemical shifts. Their long-range couplings, as observed in the gated decoupling experiment, initially suggested the new assignments shown in table 1; however, these new assignments implied relatively large two-bond ${}^{1}\text{H}{-}^{13}\text{C}$ couplings and small or nonexistent three-bond couplings. Low-power selective proton decoupling (table 2) nonetheless confirmed these assignments. Thus, irradiation of the quinone methyl protons caused a 54% decrease in the line width at one-half

²Mitomycin C 80 MHz ¹H-nmr, 0.2 M in pyridine-*d*5: 2.03 ppm, s, C₆CH₃; 2.75, m, C₂H; 3.11, d, C₁H; 3.22, s, OCH₃; 3.60, dd, C₃H; 4.02, dd, C₉H; 4.56, d, C₃H'; 5.08, t(dd), C₁₀H; 5.45, dd, C₁₀H'.

	¹ H-decoupler	$\Delta v^{1/2}$ in Hz for ¹³ C-nmr signals at (ppm)							
ppm	¹ H-assignment	104.3	106.8	110.7	176.7	178.3			
2.03 4.02 -15	C ₆ CH ₃ C ₉ H Control	10 20 22	25 28 23	11 4.5 11	14 11 12	6 13 15			

TABLE 2. Low power selective ¹H-decoupling data for mitomycin C.

height ($\Delta \nu_{1/2}$) for the 104.3 ppm signal, and the peak at 178.3 ppm narrowed by 60%. In a similar experiment on decoupling the C-9 proton, the 110.7 ppm peak collapsed to give a $\Delta \nu_{1/2}$ value that was 40% of the control value due to the abolition of long range coupling.

The three signals in the low-field aromatic region arise from C-5a, C-7, and C-10a (carbamate carbonyl), as implicated by their chemical shifts. The resonance at 149.6 ppm was shown to be due to C-7 by the observation of a 17 Hz ¹⁵N-¹³C coupling in the ¹H-decoupled ¹³C-nmr spectrum of **3**. No longer-range ¹⁵N-¹³C couplings were observed. The other two peaks in this region display no long-range ¹H-¹³C couplings, but there is a great disparity in their peak heights (*ca.* 2.5:1). The ¹H-decoupled spectrum of decarbamoylmitomycin C (**2**), which was obtained under the same experimental conditions as for mitomycin C and which shows great overall similarity with the spectrum of the parent compound, retains only the smaller peak at almost the same chemical shift as the small peak in the mitomycin C spectrum. These experiments confirmed the assignments for C-5a, C-7, and C-10a given in table 1.

The quinone carbonyl signals at 176.7 and 178.3 ppm are reassigned on the basis of their long-range 1 H- 13 C coupling patterns and the aforementioned selective decoupling of C₆CH₃.

The data presented above lead to an unambiguous assignment of the ¹³C-nmr spectrum of mitomycin C and thus to a revision of the previous assignment (5) for C-5, C-6, C-8, C-8a, and C-9a (8).

ACKNOWLEDGMENTS

We thank Dr. W.T. Bradner of Bristol Laboratoriers, Syracuse, NY, for a gift of mitomycin C; Dr. K. Takeda of the Kitasato University, Japan, for the preparation of decarbamoylmitomycin C; J.F. Kozlowski of this department for expert nmr technical assistance; the Purdue University Biochemical Magnetic Resonance Laboratory, which is supported by NIH grant RR01077 from the Division of Research Resources; and the National Cancer Institute, DHHS, for financial support through grant CA 25685.

LITERATURE CITED

- 1. R.W. Franck, Prog. Chem. Org. Nat. Prod., 38, 1 (1979).
- 2. S.K. Carter and S.T. Crooke, Eds., "Mitomycin C: Current Status and New Developments," Academic Press, New York, 1979.
- 3. U. Hornemann, In: "Antibiotics. IV. Biosynthesis," J.W. Corcoran, Ed., Springer-Verlag, Berlin, 1981, pp 295-312.
- 4. U. Hornemann, P.J. Keller, and J.F. Kozlowski, J. Am. Chem. Soc., 101, 7121 (1979).
- 5. J.W. Lown and A. Begleitr, Can. J. Chem., 52, 2331 (1974).
- 6. B.S. Iyengar, H.J. Lin, L. Cheng, W.A. Remers, and W.T. Bradner, J. Med. Chem., 24, 975 (1981).
- 7. S. Kinoshita, K. Uzu, K. Nakano, and T. Takahashi, J. Med. Chem., 14, 109 (1971).
- 8. This work is described further in P.J. Keller, Ph.D. Thesis, 1981, Purdue University.

Received 25 October 1982